May 31st 2023
Jeff Andrews, MD, FRCSC, Vice President of Medical Affairs for Integrated Diagnostic Solutions at BD, discusses the link between human papillomavirus (HPV) and cervical cancer, and how HPV self-sampling kits may increase rates of cervical cancer screening.
FDA approves dostarlimab for dMMR endometrial cancerFebruary 10th 2023
The FDA has granted a regular approval to dostarlimab-gxly (Jemperli; GSK) for adult patients with mismatch repair–deficient, recurrent or advanced endometrial cancer that has progressed on or after a prior platinum-containing regimen in any setting and who are not candidates for curative surgery or radiation.
Meagan Good shares her scare with uterine cancer to encourage people to spot the early signs of endometrial cancer as part of Eisai and advocacy partners' Spot Her campaignJune 9th 2022
Spot Her aims to educate people about the signs and risk factors of endometrial cancer, one of the most common yet under-recognized women’s cancers.
HPV and Cervical Cancer Screening Testing ConsiderationsMay 26th 2022
Experts in obstetric and gynecologic management examine conventional cervical cancer screening strategies and consider their specificity and sensitivity targets.
Awareness and Outreach for Cervical Cancer ScreeningMay 13th 2022
Drs Mark H. Stoler, Emily K. Hill, Sangini S. Sheth, and Thomas C. Wright comment on the general awareness around HPV and cervical cancer in patients as well as the importance of increasing routine cervical cancer screening approaching those conversations with patients.
Role of HPV Screening and Vaccination for Cervical CancerMay 13th 2022
Emily K. Hill, MD; Sangini S. Sheth, MD, MPH, FACOG, and Mark. H. Stoler, MD, FASCP, review the rationale of screening for HPV and vaccinating patients to prevent progression to cervical cancer.
Selinexor maintenance improves PFS in endometrial cancerFebruary 14th 2022
Frontline maintenance treatment with selinexor resulted in a statistically significant improvement in median progression-free survival vs placebo in patients with advanced or recurrent endometrial cancer, meeting the primary end point of the phase 3 SIENDO trial.
Immunotherapy approvals shine light on need for molecular testing in endometrial cancerFebruary 1st 2022
Sarah Lee, MD, MBA, discusses the use of checkpoint inhibitors in endometrial cancer, research regarding the association between MSI-H, dMMR, and TMB-H disease, and the importance of broad molecular testing to ensure all eligible patients are appropriately matched to immunotherapeutic options.
Secondary cytoreductive surgery in recurrent ovarian cancerFebruary 1st 2022
Amer Karam, MD, discusses the role of secondary cytoreductive surgery in ovarian cancer and the need for careful patient selection, plus the results from 3 clinical trials and the key differences between these efforts.
Cytology dual-stain biomarker for detecting HPV-driven cervical precancerDecember 27th 2021
A prospective observational screening study has concluded a cytology dual-stain (DS) biomarker effectively triages women who test positive for primary human papillomavirus (HPV) and are at higher risk of developing cervical cancer, irrespective of the HPV genotype.
Certain postmenopausal patients with breast cancer can avoid chemotherapy, study showsDecember 13th 2021
Certain post-menopausal women with HR-positive, HER2-negative breast cancer may be able to only undergo endocrine therapy after surgery – sparing themselves from the chemotherapy side effects.
Novel drug has potential to ‘become new standard of care’ in advanced, ER-positive breast cancerDecember 10th 2021
The study results — which were presented during the 2021 San Antonio Breast Cancer Symposium — indicated that elacestrant, a selective estrogen receptor degrader (SERD), led to a 30% reduction in the risk of disease progression or death compared with standard of care in the study population.
Niraparib Demonstrates PFS Benefit in Chinese Population With Advanced Ovarian CancerDecember 1st 2021
First-line maintenance treatment with the PARP inhibitor niraparib yielded a clinically meaningful and statistically significant improvement in progression-free survival vs placebo in Chinese patients with platinum-responsive advanced ovarian cancer, regardless of biomarker status, according to data from the phase 3 PRIME trial.
Lenvatinib plus pembrolizumab displays efficacy in advanced endometrial cancerNovember 18th 2021
The combination of lenvatinib plus pembrolizumab induced durable responses with a manageable safety profile in adults with previously treated, advanced endometrial cancer, according to a long-term follow-up analysis of a phase 1b/2 study (NCT02501096).
Lack of health insurance directly reduces cancer screening rates, most recent and long-termNovember 8th 2021
Disparities across the globe continue to surface as we approach year 2 of the COVID-19 pandemic, especially in health care. As one considers its implications, a research team from the American Cancer Society investigated its potential impact on early cancer detection.